The therapeutic importance of targeting BAFF-R is highlighted by the use of anti-BAFF-R therapies in managing myeloma, leukemia, and lymphoma, rendering BAFF-R an appealing therapeutic target in SLE as well [192]. This evidence concerns the gene TNFRSF13C and plasma cell myeloma.